OLIGONUCLEOTIDES in Europe

OLIGONUCLEOTIDES in Europe

trial

About the plant

Apeloa - Science-Driven Solutions with Global Scale

Apeloa CDMO is the contract discovery, development and manufacturing division of Apeloa Pharmaceutical Co., Ltd., a subsidiary of the Hengdian Group, one of China’s largest private enterprises. With over 30 years of industry experience, Apeloa stands as a trusted partner to global pharma and biotech companies, offering full-spectrum solutions from early-stage development to commercial-scale GMP production.

Strategically positioned across three continents, our state-of-the-art facilities and multidisciplinary teams deliver high-quality APIs, Intermediates, and Registered Starting Materials (RSMs)—all backed by robust regulatory compliance, innovation in process design, and best-in-class customer service.

Core Capabilities

•  •API Process Development & Manufacturing
•  •High-Potency API (HPAPI) – OEB4 & OEB5
•  •Flow Chemistry
•  •ADC Payloads & Linker Development
•  •Synthetic Peptides
•  •Lipid Nanoparticles (LNPs – CLs, ILs, PEG-Lipid)
•  •PROTAC/TPD Molecule Manufacturing
•  •Medicinal Chemistry (Med. Chem)
•  •Full-Time Equivalent (FTE) Research Support
•  •Analytical Development & Quality Control
•  •Global Regulatory Affairs & CMC Filing
•  •Formulation Development & Manufacturing

Global Footprint
Corporate Presence: Headquarters: Hengdian, China
Frankfurt am Main, Germany | Boston, USA | Tokyo, Japan

R&D Centers of Innovation 

Location	Facility Size	Scientists	Focus Areas
Boston, USA	16,000 sq ft	40+	Tech development, lead optimization, screening, tox batches
Shanghai, China	68,000 sq ft	300+	High-throughput screening, process development, CMC
Hengdian, China	88,000 sq ft	250+	Tech transfer, process optimization, CMC

Manufacturing Infrastructure

•  •8 globally certified manufacturing sites
• •   ?Certifications: cGMP, ISO9001, ISO14001, OSHAS18001, IPMS
  •   ?Full regulatory reach: US FDA, EMA, PMDA, NMPA, KFDA, and more
•  •Production Capacity:
  
  •   ?Chemical Synthesis:
    •    ? Total area: 11,000 m³
    •    ? Reactors: 50 L - 45,000 L
    •    ? Output API: 4,000 MT/year
    •    ? Intermediates: 38,000 MT/year
  •   ?Bio-Production:
    •    ? Total area: 6,570 m³
    •    ? Reactors: 50 L - 120,000 L
    •    ? Output API: 2,000 MT/year
    •    ? Intermediates: 2,000 MT/year
  •   ?HPAPI:
    •    ? Total reactor volume: 75 m³ (clinical & commercial scale)
    •    ? OEB 4 (PDE = 10 - 100 µg/day)
    •    ? OEB 5 (PDE < 10 µg/day)
  •   ?Multifunctional API Workshops: 658 m³ for parallel production

Why Choose Apeloa CDMO?
Reliable. Responsive. Globally Certified – Apeloa CDMO delivers flexible, science-led manufacturing with a global footprint. Whether you’re scaling a molecule or accelerating commercialization, we’re the partner that moves with your vision.

---

Certifications

---

Activity

• miRNA, siRNA, ASOs (Antisense oligonucleotides), OLIGONUCLEOTIDES manufacturing

---

Features

• Uses: Investigational, Commercial (Phase IV), Phase II, Phase III
• Toxicity (OEB classification):
• DEA: N/A
• BSL:
• Therapeutic areas: N/A
• Markets:

---

Batch Size / Reactor

• Small, Large

---

Services